SCHEMBL23852885

SCHEMBL23852885

CC(=O)c1cnc(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)nc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
USP30 Q70CQ3 1/20 0.34
HPGDS O60760 1/20 0.32
TET2 Q6N021 1/20 0.31
OGFOD1 Q8N543 1/20 0.31
TET1 Q8NFU7 1/20 0.31
EGLN2 Q96KS0 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31
HIF1AN Q9NWT6 1/20 0.31
MAPK1 P28482 1/20 0.31
PDPK1 O15530 1/20 0.31
SSTR4 P31391 1/20 0.30
ELANE P08246 1/20 0.30
CCNB2 O95067 1/20 0.30
CCNE2 O96020 1/20 0.30
CDK1 P06493 1/20 0.30
CDK4 P11802 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25383265 0.87 KDM4E (0.53) ALDH1A1KDM4EALOX15HSD17B10USP30
SCHEMBL14804139 0.83 USP30 (0.39) ALDH1A1KDM4EALOX15HSD17B10USP30
SCHEMBL14230252 0.81 USP30 (0.35) ALDH1A1KDM4EALOX15HSD17B10USP30
SCHEMBL25522851 0.81 USP30 (0.38) ALDH1A1KDM4EALOX15HSD17B10USP30
SCHEMBL31000642 0.81 GABRG2 (0.35) ALDH1A1KDM4EALOX15HSD17B10USP30
SCHEMBL2378220 0.81 SSTR4 (0.36) ALDH1A1KDM4EALOX15HSD17B10USP30
SCHEMBL5834893 0.80 GPR119 (0.38) ALDH1A1USP30HPGDSSSTR4GPR119
SCHEMBL13409594 0.79 USP30 (0.34) ALDH1A1KDM4EUSP30PDPK1SSTR4
SCHEMBL23094749 0.79 USP30 (0.34) ALDH1A1USP30PDPK1
SCHEMBL6059910 0.79 SSTR4 (0.34) ALDH1A1USP30PDPK1SSTR4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3883577-B1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY UNIV CASE WESTERN RESERVE (US) 2026-04-08 EP disclosed
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity RODEO THERAPEUTICS CORPORATION (US) 2025-06-24 US disclosed
CN-113507931-B Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2025-05-27 CN disclosed
US-20250161277-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-05-22 US disclosed
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY RODEO THERAPEUTICS CORPORATION 2023-02-09 US disclosed
CN-113507931-A Compositions and methods for modulating short-chain dehydrogenase activity 卡斯西部储备大学 2021-10-15 CN disclosed
EP-3883577-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2021-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161277-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS ALDH1A1 126/4885KDM4E 3506/4885ALOX15 28/4885
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity HPGD, GCDH, HPGDS ALDH1A1 126/4885KDM4E 3506/4885ALOX15 28/4885
US-20230039604-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS ALDH1A1 126/4885KDM4E 3506/4885ALOX15 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.